Far-infrared Therapy as a Novel Treatment for Encapsulating Peritoneal Sclerosis

July 1, 2015

Letters to the Editor

......A 45-year-old man with a medical history of end-stage renal disease was admitted owing to abdominal fullness, vomiting, and poor appetite for 1 month. The patient had received 13 years of PD followed by removal of the PD catheter owing to refractory peritonitis, resulting in a shift to hemodialysis 2 months before this admission. A physical examination showed a body temperature of 36.5 °C, a

distended abdomen and hypoactive bowel sounds. Th e dialysate effluent was dark red in appearance. Laboratory examinations

revealed normal blood leukocyte count (WBC: 7,100/mm3 ) but an elevated C-reactive protein level (50.3 mg/l). An abdominal radiograph was obtained to evaluate his symptoms. The intestinal wall was outlined by continuous calcifications (Figure 1 , arrows), and the curvilinear calcification on the right side of the radiograph was peritoneal calcification (Figure 1, white arrows). A contrast enhanced

computed tomography scan demonstrated fluid within the abdomen surrounded by thickened, enhancing peritoneum. The adherent bowel loops were collected centrally by the encapsulating calcified peritoneum, supporting the diagnosis of EPS (Figure 2, white

arrows).


Aft er 3 months of far-infrared therapy, his bowel movement improved. He was able to tolerate a regular oral diet and the color of the dialysate effluent became lightly pink. Because of the improvement in the symptoms aft er far-infrared therapy, our patient decided to follow a conservative treatment plan. Follow-up contrast-enhanced computed tomography scan showed an improvement in dilated loops of small bowel (Figure 3, white arrows). Remarkably, his nutritional status also improved with a significant increase of serum albumin level from 2.7 to 4.2 g/dl, as well as body weight from 59.1 to 62.9 kg aft er far-infrared therapy for 12 months....

-Am J Gastroenterol. 2014 Dec;109(12):1957-9.

Want to know more?



Contact us for more detail


Learn more
Questions to FIRAPY
July 16, 2025
FIRAPY Medical Japan proudly participated in the 70th Annual Meeting of the Japanese Society for Dialysis Therapy (JSDT) , held in Osaka from June 27 to 29, 2025 . This year marked a major milestone for FIRAPY in Japan: a total of 11 FIRAPY-related research presentations were featured during the congress—showcasing growing academic interest in far-infrared therapy as a supportive, non-invasive treatment in dialysis care. represents a significant milestone in FIRAPY’s ongoing academic engagement in dialysis-related research.
FIRAPY collaborates with Taipei Veterans General Hospital in research on non-invasive therapies for
July 2, 2025
FIRAPY and Taipei Veterans General Hospital co-published a study in JFMA showing improved cardiovascular and infection outcomes in peritoneal dialysis patients using far-infrared therapy.
More Posts